OncoMatch/Clinical Trials/NCT07269080
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Is NCT07269080 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for advanced solid tumor.
This is a non-randomized two-arm trial, specifically a pilot study in which patients with advanced solid tumor cancer with 3-10 metastatic lesions who are on immunotherapy will receive ablative RT to up to 10 lesions. After study intervention, participants will undergo ctDNA collection at 8 weeks after completion of ablative RT Post-treatment disease assessments, including imaging and serial ctDNA monitoring, as well as any additional treatments, will be at the discretion of the treating oncologist. Approximately 28 subjects (14 per cohort) will be enrolled. For subjects who do not complete the full planned course of RT for any reason, a final study visit should be performed approximately 30 days after the last fraction of radiation. If a subject is discontinued from the study with an ongoing adverse event or an unresolved clinically significant laboratory result, the clinical investigative team will attempt to provide follow-up until a satisfactory clinical resolution of the laboratory result or adverse event is achieved.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunotherapy (PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, LAG-3 inhibitor)
Subjects receiving treatment for >3 months with an FDA-approved immunotherapy agent such as a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, or an LAG-3 inhibitor; either as monotherapy or in combination with another FDA-approved immunotherapy agent. Subjects may have received prior combination cytotoxic chemotherapy and immunotherapy, but must be receiving only immunotherapy for at least 30 days prior to registration.
Lab requirements
Blood counts
Demonstrates adequate organ function.
Kidney function
Demonstrates adequate organ function.
Liver function
Demonstrates adequate organ function. For patients with liver metastases, moderate/severe liver dysfunction (Child-Pugh B or C) excluded.
Demonstrates adequate organ function. For patients with liver metastases, moderate/severe liver dysfunction (Child-Pugh B or C) excluded.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois at Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify